Biopharma Deal Value, Volume Tumbled Substantially During First Half
BY JOSEPH HAAS Executive Summary A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
The biopharmaceutical industry has fared better than many others during the COVID-19 pandemic, but it hasn’t escaped disruption. A new PwC analysis shows that deal-making decreased precipitously during the first six months of 2020, both by aggregate value and volume. In a survey of deals valued at $15m or higher, PwC analysts found just $3.3bn in total big pharma deal value during the second quarter of 2020, even though the total number of deals rose from 19 during the first quarter to 22 during the second. Aggregate deal value in big pharma during the quarter was the lowest since the first quarter of 2018, the firm’s mid-year 2020 Global Pharma & Life Sciences Deals Insights report notes. “Key industry players are focusing resources internally right now and not on inorganic growth,” PwC stated. “As many companies redirect
8 / September 2020
© Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
